L’Oréal has acquired Lactobio, a Dabish probiotic and microbiome research company based in Copenhagen.
Lactobio was founded in 2017 by Søren Kjærulff and Charlotte Vedel, who developed a proprietary microbiome discovery platform and screening method to select the most effective and safe strains.
These precision probiotics, created from a large biobank of Lactobacillus bacteria, will be used in the development of topical formulations containing live bacteria, taking inspiration from nature to impart numerous benefits to skin and hair.
L’Oréal said the acquisition builds on 20 years of research into the microbiome scientific territory and deepening its knowledge of the microorganisms that live on the skin’s surface.
It also opens up, adds the French beauty giant, new scientific opportunities, including leveraging Lactobio’s microbiome expertise and significant IP portfolio to develop safe and effective new cosmetic solutions using live bacteria.
“The integration of Lactobio into our Advanced Research is highly complementary: L’Oréal’s strong scientific knowledge and technological advancements coupled with Lactobio’s best-in-class formulations using living organisms will significantly strengthen and accelerate our microbiome research dedicated to beauty,” said Anne Colonna, Global Head of Advanced Research of L’Oréal Groupe.
“By joining forces, we aim to develop a new generation of cosmetics that will use cutting-edge innovations in the formulation process to provide science-based, precision probiotic and postbiotic products with new performance levels,” she added.
A report from ingredients supplier Henley Bridge has warned that cocoa price increases of 15-20% for the first half of 2024 might continue into the second half of the year. Despite growth in global cocoa supply in 2021, unfavourable weather conditions and demand from emerging markets have led to supply deficits.
By carving out the ANH business, DSM-Firmenich would focus fully on its Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care divisions. Full focus on these businesses is expected to enhance commercial potential and synergies, supporting “consistent growth outlook alongside robust margins”.
Cargill and Enough are expanding their partnership to further develop nutritious and sustainable alternative meat and dairy solutions. Cargill has signed a commercial agreement to use and market Enough’s Abunda protein and has also invested in the company’s Series C growth funding round.